An Open-Label Sunitinib Malate (SU011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment.
18 Years
N/A
Both
Metastatic Breast Cancer, Advanced Breast Cancer, Advanced Gastric Cancer, Advanced/Metastatic Non-small Cell Lung Cancer, Gastrointestinal Stromal Tumor, Hepatocellular Carcinoma, Metastatic Castration-resistant Prostate Cancer, Metastatic Renal Cell Cancer, Non Small Cell Lung Cancer, Pancreatic Islet Cell Carcinoma, Pancreatic Neuroendocrine Tumor, Thyroid Cancer
Trial Information
An Open-Label Sunitinib Malate (SU011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment.
Inclusion Criteria:
- Must have ended treatment from one of the following sunitinib studies: A6181030,
A6181064, A6181078, A6181087, A6181094, A6181107, A6181108, A6181110, A6181111,
A6181112, A6181113, A6181120, A6181126 and A6181170. Other Pfizer sponsored
sunitinib studies may be included in the future.
Exclusion Criteria:
- See inclusion criteria
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
The objective of the study is to assess long term safety and tolerability of patients enrolling from prior Sutent clinical studies. Duration of clinical benefit will be assessed for patients enrolling from protocol A6181111; PNET.
Outcome Time Frame:
duration of study
Safety Issue:
Yes
Principal Investigator
Pfizer CT.gov Call Center
Investigator Role:
Study Director
Investigator Affiliation:
Pfizer
Authority:
United States: Food and Drug Administration
Study ID:
A6181114
NCT ID:
NCT00428220
Start Date:
July 2007
Completion Date:
May 2014
Related Keywords:
- Metastatic Breast Cancer
- Advanced Breast Cancer
- Advanced Gastric Cancer
- Advanced/Metastatic Non-Small Cell Lung Cancer
- Gastrointestinal Stromal Tumor
- Hepatocellular Carcinoma
- Metastatic Castration-Resistant Prostate Cancer
- Metastatic Renal Cell Cancer
- Non Small Cell Lung Cancer
- Pancreatic Islet Cell Carcinoma
- Pancreatic Neuroendocrine Tumor
- Thyroid Cancer
- Potentially other tumor types in the future
- Breast Neoplasms
- Carcinoma
- Thyroid Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Lung Neoplasms
- Stomach Neoplasms
- Prostatic Neoplasms
- Neuroendocrine Tumors
- Gastrointestinal Stromal Tumors
- Adenoma, Islet Cell
- Carcinoma, Islet Cell
- Carcinoma, Hepatocellular
Name | Location |
|---|---|
| Pfizer Investigational Site | Atlanta, Georgia 30342 |
| Pfizer Investigational Site | Springfield, Illinois 62701-1014 |
| Pfizer Investigational Site | Houston, Texas 77030 |
| Pfizer Investigational Site | Richmond, Virginia 23249 |
| Pfizer Investigational Site | Cedar Rapids, Iowa 52403 |
| Pfizer Investigational Site | Columbia, Missouri 65201 |
| Pfizer Investigational Site | Las Vegas, Nevada 89128 |
| Pfizer Investigational Site | Eugene, Oregon 97401 |
